Supreme Court unanimously concludes that anti-abortion groups have no standing to challenge access to mifepristone – but the drug likely faces more court challenges
Publisher
The Conversation
Date
2024-6-13
In Food and Drug Administration v. Alliance for Hippocratic Medicine, the plaintiffs argued that the FDA had not adequately tested mifepristone for safety. They also claimed that the FDA’s subsequent changes, which made the drug even more widely available, were also flawed. In 2016, the FDA expanded the time frame for prescription of mifepristone from seven weeks to 10 weeks gestation and allowed nonphysician health care providers, like nurse practitioners, to prescribe the pill. Then, in 2021, the FDA removed the in-person dispensing requirement and allowed certified pharmacies to distribute it.
Citation
Naomi R. Cahn & Sonia Suter, Supreme Court unanimously concludes that anti-abortion groups have no standing to challenge access to mifepristone – but the drug likely faces more court challenges, The Conversation (June 13, 2024).